studies finding mrna vaccine spike in cancer tumors

The retrieved studies do not contain a single paper that directly tested for mRNA vaccine spike protein inside human cancer tumors.

The evidence block is a mixed bag. One narrative review [1] cites a Japanese ecological study showing a rise in age-adjusted cancer mortality after the third-dose campaign, and it mentions that in a melanoma model, a fully modified mRNA vaccine stimulated cancer growth and metastasis [1]. Another study [2] used a spike-derived peptide as an adjuvant in a cancer vaccine—meaning it was deliberately injected into tumors to boost immune attack—and found it improved anti-PD-L1 therapy in mice. That is the opposite of accidental spike accumulation.

What the retrieval does show is that vaccine-derived spike fragments persist in the blood of about 50% of recipients for 3 to 6 months [1], and that the mRNA can be reverse-transcribed and integrated into chromosomes in human cancer cell lines in a dish [1]. Those are signals that the material reaches tissues and can linger. But no study here biopsied a human tumor and tested for the spike protein inside it. That question remains unstudied in the retrieved literature.

My call: the evidence for spike protein accumulating in human tumors is absent from these records. The mechanism is plausible—the material circulates and can enter cells—but no study here looked for it where the question asks. Confidence: low, because the question was not answered by the retrieved evidence.